Crossmark

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

Crossref DOI link: https://doi.org/10.1186/s12936-019-2730-1

Published Online: 2019-03-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ishengoma, Deus S. http://orcid.org/0000-0003-4317-4425
Mandara, Celine I.

Francis, Filbert

Talundzic, Eldin

Lucchi, Naomi W.

Ngasala, Billy

Kabanywanyi, Abdunoor M.

Mahende, Muhidin K.

Kamugisha, Erasmus

Kavishe, Reginald A.

Muro, Florida

Mohamed, Ally

Mandike, Renata

Mkude, Sigsbert

Chacky, Frank

Paxton, Lynn

Greer, George

Kitojo, Chonge A.

Njau, Ritha

Martin, Troy

Venkatesan, Meera

Warsame, Marian

Halsey, Eric S.

Udhayakumar, Venkatachalam
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03387631 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania
https://doi.org/10.1186/s12936-019-2730-1
Funding

Funding for this research was provided by:

USAID
License Information

Text and Data Mining valid from 2019-03-21

Version of Record valid from 2019-03-21
More Information

Article History

Received: 14 January 2019

Accepted: 14 March 2019

First Online: 21 March 2019

Document is current

Any future updates will be listed below